Bridged compound with central pyrrolidine units, an intermediate compound for the preparation of the bridged compound, a process for producing the bridged compound, use of the bridged compound for the manufacture of a medicament, a pharmaceutical composition, a method of preparing a pharmaceutical composition and a method for the preparation of a pharmaceutically acceptable salt of a non-salt compound
Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula (I) or (II) or a salt thereof, in which R1, R2, R3, R100, R200, R300, A, A1, BG, Q and Q1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.Linvention concerne un isomère, un énantiomère, un diastéréoisomère ou un tautomère dun composé représenté par la formule (I) ou (II) ou dun sel dudit composé, formule dans laquelle R1, R2, R3, R100, R200, R300,A, A1, BG, Q et Q1 sont des substituants selon linvention. Cette invention concerne également lutilisation de composés de formule I et II pour traiter des maladies prolifératives telles que le cancer.
